Kanglong Huacheng: plans to invest 3 billion yuan to build a project with annual production of 200 tons of pharmaceutical intermediates and APIs.

Kanglong Huacheng announcement, the company plans to build a project with an annual output of 200 tons of pharmaceutical intermediates and APIs in Hangzhou Bay Shangyu Economic and Technological Development Zone of Shaoxing City through its wholly-owned subsidiary Kanglong Huacheng Pharmaceutical New Drug Production Co., Ltd. The total investment of the project is 3 billion yuan, and the first phase of the project is expected to be put into use in 2028, while the second phase is expected to be put into use in 2030. The project aims to expand the production capacity of high-end pharmaceutical intermediates and APIs, strengthen the application ability of green manufacturing technology, and enhance the CDMO service capability from pre-clinical to commercialization. The implementation of the project is expected to have no significant impact on the company's financial condition and operating results in 2026; the impact on future annual operating performance will depend on the progress of project construction and the company's order situation.